Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. The neuromodulatory agent has one or more of the following characteristics: it is capable of inducing remyelination; binding to neural tissue; promoting Ca++ signaling with oligodendrocytes; and promoting cellular proliferation of glial cells. Amino acid and DNA sequences of exemplary antibodies are disclosed.

Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. The neuromodulatory agent has one or more of the following characteristics: it is capable of inducing remyelination; binding to neural tissue; promoting Ca++ signaling with oligodendrocytes; and promoting cellular proliferation of glial cells. Amino acid and DNA sequences of exemplary antibodies are disclosed.

Abstract: The present invention is drawn to a pharmaceutical compound for the treatment of posterior retinal diseases through topical application of the compound. The compound includes an effective amount of a therapeutic compound, and at least one additional agent that helps to prolong the residence time of the therapeutic compound within the extraocular space, or increase the transport of the therapeutic compound across a tissue of an eye toward and into a posterior ocular region, or both. The invention is additionally drawn to a device and method for delivering the compound.

Abstract: The present invention relates to 1-arylsulfonyl-3 substituted indole or indoline derivatives having the general formula (I) (I) wherein the dotted line represents an optional bond; n is 0 or 1; m is 0-5 and Ar, R6-R11 are defined in the description. The invention further relates to pharmaceutical compositions comprising said derivatives, and to the use of these 1-arylsulfonyl-3-substituted indole or indoline derivatives in the treatment of central nervous disorders such as psychosis, schizophrenia, manic depressions, depressions, neurological disorders, cognitive enhancement, Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease and Huntington's disease.

Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. The neuromodulatory agent has one or more of the following characteristics: it is capable of inducing remyelination; binding to neural tissue; promoting Ca?? signaling with oligodendrocytes; and promoting cellular proliferation of glial cells. Amino acid and DNA sequences of exemplary antibodies are disclosed.

Abstract: The present invention is drawn to a pharmaceutical compound for the treatment of posterior retinal diseases through topical application of the compound. The compound includes an effective amount of a therapeutic compound, and at least one additional agent that helps to prolong the residence time of the therapeutic compound within the extraocular space, or increase the transport of the therapeutic compound across a tissue of an eye toward and into a posterior ocular region, or both. The invention is additionally drawn to a device and method for delivering the compound.

Abstract: The present invention relates to chemical compounds, methods for their discovery, and their therapeutic use. In particular, the present invention provides compounds as inhibitors of alphaviruses.

Abstract: Apparatus and methodology for compacting to a final, lock-stabilized bundle an initial charge of randomly and chaotically arrayed, loose pieces of scrap metal, and also a final, lock-stabilized bundle of such material, per se.

Abstract: Under the present invention, when a request for a certificate is made, a set of (mapping) rules are used to identify an appropriate directory and any other information sources, and to retrieve information for the certificate therefrom. The directory name is then transformed using the set of rules for use in the certificate. Thereafter, a template for the certificate is developed using the set of rules. The template and the request are then communicated to the PKI, which will generate and return the certificate. Upon receipt, the present invention can verify that the certificate actually includes the transformed name.

Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. The neuromodulatory agent has one or more of the following characteristics: it is capable of inducing remyelination; binding to neural tissue; promoting Ca?? signaling with oligodendrocytes; and promoting cellular proliferation of glial cells. Amino acid and DNA sequences of exemplary antibodies are disclosed.

Abstract: Under the present invention, a first (e.g., unedited) set of code will be compiled and analyzed to produce a first set of results that includes a set of errors. A second set of code, which represent an edited version of the first set of code will be compiled and analyzed to produce a set of results that includes another set of errors. Thereafter, the second set of errors will be filters so that errors appearing from the compilation and analysis of the first set of code are excluded. This filtered set of errors can than be presented to the user. The present invention will leverage, among other things, a static code analyzer and a filtering tool to achieve these results.

Abstract: The present invention provides a method, system, and computer program product for transparent on-demand certificate provisioning for secure email. The method comprises: generating a keypair and a self-signed certificate; requesting a certificate from a certification authority; temporarily securing email using the self-signed certificate; and securing email using the requested certificate, after receipt of the requested certificate from the certification authority. The present inventions uses self-signed certificates as an initial, interim security mechanism, provides automatic submission of certificate requests and renewal requests, provides an administrative policy to specify when keypairs and self-signed certificates are generated by a user's client system, and when certificate requests are submitted, and provides automatic transition from end-user defined trust to delegated trust based upon CA-issued certificates.

Abstract: Antibodies, and particularly human antibodies, are disclosed that demonstrate activity in the treatment of demyelinating diseases as well as other diseases of the central nervous system that are of viral, bacterial or idiopathic origin, including neural dysfunction caused by spinal cord injury. Neuromodulatory agents are set forth that include and comprise a material selected from the group consisting of an antibody capable of binding structures or cells in the central nervous system, a peptide analog, a hapten, active fragments thereof, agonists thereof, mimics thereof, monomers thereof and combinations thereof. The neuromodulatory agent has one or more of the following characteristics: it is capable of inducing remyelination; binding to neural tissue; promoting Ca++ signaling with oligodendrocytes; and promoting cellular proliferation of glial cells. Amino acid and DNA sequences of exemplary antibodies are disclosed.

Abstract: A method and apparatus for making fuel cell components via a roll to roll process are described. Spaced apart apertures are cut in first and second gasket webs that each include adhesives. The first and second gasket webs are transported to a bonding station on conveyers. A membrane web that includes at least an electrolyte membrane is also transported to the bonding station. At the bonding station, a gasketed membrane web is formed by attaching the first and second gasket webs to the membrane web. The first gasket web is attached to a first surface of the membrane web via the adhesive layer of the first gasket web. The second gasket web is attached to a second surface of the membrane web via the adhesive layer of the second gasket web.

Abstract: An iontophoretic method for transporting compounds of interest across a body tissue is provided. The method utilizes an AC signal in conjunction with a barrier-modifying agent such as a fatty acid, fatty alcohol, bile acid, surfactant, or the like. The method enables the maintenance of a substantially constant electrical state in a localized region of the tissue through which transport occurs, thereby allowing a compound of interest to be transported across the tissue in a controlled and predictable manner. The barrier-modifying agent reduces the time as well as the voltage level required to achieve a target electrical resistance, thereby reducing patient discomfort and increasing the battery life of the iontophoresis device.

Abstract: A printing system and method are provided that facilitate the mobile printing of a document. The printing system comprises an automated print agent located in a device coupled to a network. The printing system also comprises a network alias associated with a printer coupled to the network, where the automated print agent acting as a network destination for a transmitted document addressed to the network alias. The automated print agent orchestrates the printing of the transmitted document on the printer upon receipt of the transmitted document from a transmitting device.

Abstract: A power and power management signaling circuit in a network interface card (NIC) for all known Wake On LAN PCI bus configurations includes a single voltage regulator together with connections to a network-initiated power management recovery signal MPT—PMEN from the network interface, power management recovery and auxiliary power signals PME—N and AUX3V within the PCI bus, and a system motherboard header. A first inverter inverts MPT—PMEN to the PME signal for the header, while a second inverter gates auxiliary power AUXVDD to main power PCIVDD for the NIC when the PCI system power PCI5V is asserted. Diodes prevent back powering of the PCI bus during hibernate states, system power short circuiting and leakage malfunctions when the header is incorrectly connected or unconnected, and auxiliary power shorts to ground when the previously undefined AUX3V PCI bus line is grounded.

Abstract: A system, method, and program embodied on a computer readable medium are provided for configuring the automated print agent for printing. In one embodiment, the method comprises receiving an email print message addressed to a network alias, the network alias being associated with an automated print agent employed for performing an email print, identifying a printer specified in the email print message, determining if the automated print agent is configured for printing to the printer, and, automatically configuring the automated print agent to print to the printer upon a determination that the automated print agent is not configured to print to the printer.

Abstract: A method and facility for displaying information about a multitude of different customers. The method includes, for each customer, receiving a set of numeric values, each associated with one of a plurality of different parameters. A symbol is generated for each customer, and the symbols are spatially arranged, based on the numeric values. The method may include collecting customer interactions during web browsing, and converting interaction data to a limited data set of the values for display and storage. The values may be displayed in three dimensional format for viewing, and may be revised over time and as additional customer interactions occur.

Abstract: A jack shaft garage door operator for opening and closing a movable garage door has a drive containing an electric motor. A rotatable jack shaft is connected to the drive unit to be driven thereby. A pull-up cable drum is connected to and driven by the jack shaft. A pull-up cable extends from the drum about which it is wound and connects to a bottom part of the garage door to raise the door. A pivoting arm is mounted near the jack shaft and provides tension to the cable. A shaft lock hub mounted on the jack shaft is engaged and locked by the arm if the tension in the cable drops. A stop is mounted on the garage door for engagement by the movable arm in the event that the door is opened without the cable being drawn in the cable drum.